EP0796108A2 - Compositions a base d'ubiquinones solubles dans l'eau, precurseurs de medicaments, ainsi que les procedes y ayant trait - Google Patents

Compositions a base d'ubiquinones solubles dans l'eau, precurseurs de medicaments, ainsi que les procedes y ayant trait

Info

Publication number
EP0796108A2
EP0796108A2 EP95943698A EP95943698A EP0796108A2 EP 0796108 A2 EP0796108 A2 EP 0796108A2 EP 95943698 A EP95943698 A EP 95943698A EP 95943698 A EP95943698 A EP 95943698A EP 0796108 A2 EP0796108 A2 EP 0796108A2
Authority
EP
European Patent Office
Prior art keywords
ubiquinone
prodrug
moiety
solubilizing
apoptosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95943698A
Other languages
German (de)
English (en)
Inventor
A. Charles Morgan, Jr.
Scott S. Graves
Clive S. Woodhouse
Marianna Sikorska
Roy Walker
D. Scott Wilbur
Henryk Borowy-Borowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Council of Canada
RYAN PHARMACEUTICALS Inc
University of Washington
Original Assignee
National Research Council of Canada
RYAN PHARMACEUTICALS Inc
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research Council of Canada, RYAN PHARMACEUTICALS Inc, University of Washington filed Critical National Research Council of Canada
Publication of EP0796108A2 publication Critical patent/EP0796108A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Definitions

  • the present invention generally relates to a water soluble ubiquinone compositions and prodrugs, methods of their delivery, and methods of their use in the amelioration of apoptosis.
  • Ubiquinones specifically coenzyme Qio (CoQlO)
  • CoQlO coenzyme Qio
  • Aqueous formulations are advantageous because such formulations allow for great flexibility in modes of administration, in particular, allowing for parental administration, while allowing for high concentrations of CoQlO in lesser volumes and greater bioavailabilty.
  • Intravenous formulations are particularly advantageous because of dependability, accuracy, and convenience of such formulations.
  • Intravenous formulations also avoid gastric irritation which potentially accompanies oral administration of drugs.
  • Intravenous formulations allow for continuous, as well as intermittent, drug therapy. Further, this method of administration is particularly valuable when the patient is unable to ingest an oral dosage due to, a malabsorption syndrome, an intolerance, lack of consciousness, or nausea.
  • a fluid formulation, particularly a concentrated solution, of CoQlO is of great value in formulating CoQlO capsules.
  • highly hydrophobic drugs are poorly absorbed in the gastrointestinal tract. Due to the slow rates of absorption of CoQlO from the gastrointestinal tract (6-10 h) and a period of about seven days to reach steady-state plasma levels, in most cases oral delivery cannot be used for the treatment of acute illness.
  • a clinically effective and usable aqueous formulation of CoQlO should be stable at common ambient temperatures and remain essentially unchanged in dispersion characteristics for a period of at least a year. This is the approximate period which is required for preparation, analysis, shipment to distribution centers, shipment to and storage in hospitals for use and administration to a patient.
  • the dispersion of solid particles of water-insoluble CoQlO in an aqueous medium renders the preparation of such a formulation very difficult.
  • Solid particle dispersions have been attempted, but particles containing CoQlO precipitate in the solution and redispersion methods such as stirring or shaking are not acceptable for clinical use.
  • a second prominent difficulty associated with the insolubility of CoQlO is having a formulation which on intravenous administration, does not lead to particle separation or precipitation within the bloodstream. Such a separation or precipitation would be detrimental to blood flow and potentially life threatening.
  • CoQlO has been labeled a "breakthrough" drug in congestive heart failure - showing clinical benefit in 75% of patients (Greenberg and Frishman, J. Clin. Pharmacol. 30:596-608, 1990; Oda, Dru g s EXP. Clin. Res. 11:557-76, 1985).
  • CoQlO has been used to combat the effects of muscular dystrophy, producing clinical benefit in a subpopulation of patients with Duchenne form (Folkers et al., Proc. Natl. Acad. Sci. U.S.A.
  • CoQlO has been successfully utilized to battle periodontal disease (Wilkinson et al., Res. Commun. Chem. Pathol. Pharmacol. 14:715-9, 1976). CoQlO has been implicated in the reduction in toxicity of chemotherapeutic drugs, e.g., cardiac toxicity of adriamycin (R. Ogura et al., J. Nutr. Sci. Vitaminol. 28:329-34, 1982). CoQlO has been successfully implemented in the correction of drug-induced deficiencies, e.g., psychotherapeutic, diabetes and beta-blocker drugs ( atsumoto and Inoue, Jpn. Circ. J. 47:356-62, 1983).
  • CoQlO has been used in immune restoration, e.g., aging, AIDS, allergies (Suzuki et al., Jpn J. Sure. 16:152-5, 1986; Folkers et al., Res. Commun. Chem. Pathol. Pharmacol. 38:335-8, 1982; Folkers et al., Biochem. Biophvs. Res. Commun. 193:88-92, 1993).
  • a common denominator in many of these disorders is the presence of ongoing apoptosis.
  • Apoptosis, or programmed cell death is the major type of cell death in various physiological processes that lead to remodeling of developing embryos and adult cell turnover.
  • Apoptosis is also responsible for the removal of transformed or virus infected cells, and cells damaged via the release of reactive oxygen species, cytotoxic agents, macrophages and cytotoxic T-lymphocytes. Furthermore, apoptosis occurs in various pathological states, including such diverse diseases as AIDS and cancer, and likely occurs around cell injury sites like that surrounding myocardial infarction. Apoptosis is characterized by compaction of the nuclear chromatin into dense masses, convolution, fragmentation of the nucleus, and blebbing of the plasma membrane ultimately resulting in cell death.
  • Free radicals are continuously generated in every cell as a product of normal cellular function (e.g., oxygen metabolism and drug metabolism). However, if the concentration of free radicals in a cell exceeds a minimum toxic concentration (MTC), the structural and functional efficiency of lipids, proteins, carbohydrates, and nucleic acids—all vital components to the functioning cell—are altered. This "cellular damage" is a typical result of oxidative stress.
  • MTC minimum toxic concentration
  • free radical scavengers throughout every cell in the body assures the stabilization and integrity of cell membranes.
  • free radical scavengers are present in excessive concentrations in order to assure the cell a stable environment, although the absolute concentration of free radical scavengers present in cells varies from individual to individual.
  • free radical scavenger activity in an individual may be altered by a broad spectrum of influencing factors.
  • the scavenging ability of the enzymes in a specific individual is determined by measuring the rate at which the free radical scavenger can neutralize a given number of free radicals. This rate is designated the "free radical scavenger activity.”
  • the free radical scavenger activity maintains free radicals at concentrations well below the minimum toxic concentration ("MTC").
  • MTC minimum toxic concentration
  • a variety of factors may increase the free radical concentration, thereby endangering the patient.
  • factors include considerations of genetics, nutritional status, exposure to drug therapy, drug metabolism, disease, and environmental factors. A change in any one of these factors may result in a failure of the body's defensive mechanisms and result in apoptosis.
  • cellular energy levels in the form of ATP or mitochondrial activity may be key in the prevention in cell death.
  • Smets et al. have reported that there is an inverse relationship between the level of cellular ATP and sensitivity to glucocorticoid-induced apoptosis (Blood 84(5 ⁇ : 1613. 1994). Consequently, inhibitors of mitochondrial respiration potentiate cell sensitivity to glucocorticoid action. Therefore, methods that increase the production of ATP through mitochondrial activity would protect cells from agents that induce apoptotic cell death.
  • CoQlO Due to the ability of CoQlO to both act as a free radical scavenger in membranes and to offset the inability of cells to manufacture sufficient energy for cellular repair, CoQlO possesses functional activities ideal for an inhibitor of apoptosis.
  • Current ubiquinone formulations are limited in their ability to achieve desired bioavailability and solubility for clinical effectiveness, and thus it is apparent that there exists a need for new and additional methods and compositions which address and rectify the problem.
  • the present invention fulfills this need, and further provides related advantages.
  • One aspect of the present invention includes a water soluble ubiquinone prodrug comprising a ubiquinol substituted at at least one of positions Cl and C4 of the ubiquinol with a substituent independently selected from a solubilizing moiety and a targeting moiety.
  • the ubiquinone prodrugs of this invention have C6 terpenoid side chains having from 1 to 12 isoprenoid units, preferably 6 to 10 units, and most preferably 10 units.
  • the substituent solubilizing moiety is further coupled to a targeting moiety.
  • the substituent targeting moiety is further coupled to a solubilizing moiety.
  • the solubilizing moiety is a targeting group.
  • the solubilizing moiety or targeting moiety is coupled to the ubiquinol through a linking group selected from carbamate, ether, ester, and carbonate linking groups.
  • the solubilizing moiety is selected from an electronically charged and an electronically neutral solubilizing moiety.
  • Representative electronically charged solubilizing moieties include moieties having a single charged group selected from sulfonate, carboxylate, phosphonate, and ammonium groups, as well as porycationic and polyanionic moieties including polypeptides.
  • Representative electronically neutral solubilizing moieties include moieties having single solubilizing groups such as hydroxy, ether, amine, and thiol groups, as well as polyalcohol, polyether, and polyamine moieties.
  • the solubilizing moiety is a polyether such as polyethylene glycol having a molecular weight in range of about 350 to about 6000, preferably in range of about 600 to about 3400, and most preferably in a range from about 1500 to about 2500.
  • the ubiquinone prodrug comprises a ubiquinone(50) linked to a polyethylene glycol 5000.
  • a targeting moiety is directed to a receptor selected from LDL receptors, asialoglycoprotein receptors, polyamine receptors, insulin receptors, transferrin receptors, and alpha-2-macroglobulin receptors.
  • the targeting moiety is an asialoglycoprotein.
  • Another aspect of the present invention includes a pharmaceutical composition comprising a ubiquinone prodrug and optionally a pharmaceutically acceptable excipient or diluent.
  • a ubiquinone delivery composition comprised of a ubiquinone and a solubilizing agent, wherein the solubilizing agent is comprised of a lipophilic moiety coupled to a solubilizing moiety.
  • a lipophilic moiety is selected from a lipid or a phospholipid including fatty acids, fatty alcohols, and fatty esters.
  • the lipophilic moiety is a sterol.
  • Representative solubilizing moieties include electronically neutral solubilizing moieties, such as polyethers including polyethylene glycols having a molecular weight generally in the range of 350-6000, and preferably in the range of about 1500 to about 2500.
  • the ubiquinone delivery composition includes a ubiquinone prodrug and a solubilizing agent. In a further embodiment, the ubiquinone delivery composition includes a ubiquinone, a ubiquinone prodrug, and a solubilizing agent.
  • a pharmaceutical composition comprising a ubiquinone delivery composition and optionally a pharmaceutically acceptable excipient or diluent is provided.
  • Another aspect of the present invention is directed to a method of ubiquinone delivery to a warm-blooded animal utilizing a ubiquinone delivery composition.
  • the method utilizes a ubiquinone prodrug
  • the method utilizes a pharmaceutical composition comprising a ubiquinone prodrug or a ubiquinone delivery composition.
  • the present invention further provides methods for ameliorating apoptosis in a warm ⁇ blooded animal and/or a biological preparation.
  • One aspect of the present invention therefore, provides a method of ameliorating apoptosis comprising administering to a warm ⁇ blooded animal in need thereof a therapeutically effective amount of a water soluble ubiquinone prodrug or a ubiquinone delivery composition.
  • the apoptosis may be associated with ischemia, a viral disorder, or a neurodengenerative disorder, for example.
  • FIGURE 1 is a schematic representing the redox cycling of a ubiquinone.
  • Formula 1 represents ubiquinone.
  • Formula represents ubiquinol;
  • FIGURE 2 is a formula representing ubiquinol with the coupling sites for the solubilizing moieties of the present invention indicated by X, as well as further exemplary cleavable linking groups suitable for use in the present invention;
  • FIGURE 3 is a photograph of a hematoxylin/eosin stained paraffin section of a brain of a rat in which brain ischemia was induced.
  • This rat was not treated prior to or after the induction of ischemia.
  • the rat and brain were prepared as outlined in Example 8 below. Briefly, brain ischemia was induced in this rat by bilateral occlusion of common carotid arteries for 8 minutes. The rat was perfused with 4% buffered formalin and the brain tissue was removed and embedded in paraffin 3 days after ischemia.
  • the photograph shows significant neuronal cell death as indicated by apoptotic cells identified by dark cells designated 'a' in the photograph;
  • FIGURE 4 is a photograph of a rat brain prepared as described above for FIGURE 3, however this rat was treated with CoQlO by administering a ubiquinone delivery composition of the present invention as outlined in Example 8.
  • the photograph shows little or no neuronal cell death.
  • non-apoptotic neuronal cells are designated 'b';
  • FIGURE 5 is a table that summarizes the percentage of apoptotic neuronal cells for rats treated with a representative ubiquinone delivery composition compared to untreated rats as a function of days after reperfusion following indication of brain ischemia by 8- and 12- minute arterial occlusion as outlined in Example 8; and
  • FIGURE 6 is a table that summarizes the bioavailability of CoQlO in rats following administration by intraperitoneal injection of aqueous solutions a representative ubiquinone delivery composition and ubiquinone prodrugs. The table presents CoQlO levels and the percent increase in CoQlO level following administration of the ubiquinone delivery composition and prodrugs.
  • the present invention provides water soluble ubiquinone derivatives and related compositions and methods for the treatment of a wide variety of disorders characterized by apoptosis.
  • the present invention enables increased bioavailability of ubiquinones and facilitates administration of ubiquinones through increasing the water solubility of compositions effective in their delivery and providing ubiquinone prodrugs that are highly water soluble.
  • ubiquinones are a group of lipid soluble benzoquinones some of which are involved in mitochondrial electron transport.
  • ubiquinones have a 2,3- dimethoxy-5-methylbenzoquinone nucleus and a variable terpenoid side chain containing from one to twelve mono-unsaturated /r ⁇ ns-isoprenoid units (see the general structure below).
  • the differences in properties among ubiquinones has been attributed to the difference in length of the terpenoid side chain.
  • a dual nomenclature exists for these compounds and is based upon the length of the terpenoid side chain.
  • a benzoquinone of this family is therefore properly referred to as either “coenzyme Q drum” where n is from one to twelve and designates the number of isoprenoid units in the side chain, or alternatively, "ubiquinone (x)" where x designates the total number of carbon atoms in the side chain and is a multiple of five.
  • coenzyme Q reading where n is from one to twelve and designates the number of isoprenoid units in the side chain
  • ubiquinone (x) where x designates the total number of carbon atoms in the side chain and is a multiple of five.
  • coenzyme Q10 the most common ubiquinone in animals
  • ubiquinone (50) the most common ubiquinone in animals has a ten isoprenoid side chain and is referred to as either coenzyme Q10 or ubiquinone (50).
  • Ubiquinones including coenzyme Q10 (CoQlO) are essentially insoluble in aqueous media. This insolubility may be attributed to the long hydrocarbon isoprenoid side chain which bestows the molecule with its extremely lipophilic characteristics. These characteristics, among other effects, appear to be the source of the very slow absorption rates of the molecule.
  • Pharmacokinetic data has demonstrated that intestinal absorption of ubiquinones is slow and inefficient in human subjects.
  • after administration of CoQlO there is a lag time of about one hour before increased plasma levels of CoQlO can be detected. A second absorption peak appears after about 24 hours. Approximately seven days of administration is required to achieve maximum steady-state plasma levels.
  • absorption of orally administered CoQlO is variable and generally in the range of only about 2-5 %.
  • water soluble ubiquinone derivatives are disclosed. These ubiquinone derivatives are water soluble ubiquinone prodrugs that include a solubilizing moiety which provides the water soluble properties to the ubiquinone prodrug.
  • prodrug refers to a chemical compound that is converted in vivo to an active therapeutic agent by a metabolic process or biochemical or physiological condition. Thus, upon exposure to in vivo conditions including, by way of example, enzymatic activity, the ubiquinone prodrug is converted to a ubiquinone.
  • a ubiquinone prodrug additionally includes a targeting moiety, which directs the compound to a specific site in the body or the cell.
  • ubiquinone delivery compositions include a ubiquinone and/or a water soluble ubiquinone prodrug in combination with a solubilizing agent.
  • the solubilizing agent facilitates the effective administration of a ubiquinone or ubiquinone prodrug to a warm ⁇ blooded animal to elicit a therapeutic effect.
  • a method of ubiquinone delivery utilizing a ubiquinone delivery composition is provided.
  • apoptosis an example of a therapeutic effect
  • delivery of the ubiquinone is accomplished either through the use of a water soluble ubiquinone prodrug or a ubiquinone delivery composition.
  • the antioxidant properties of the ubiquinone function to scavenge free radicals.
  • ubiquinone includes compounds represented by the following general formula 1:
  • small changes may be made to the ubiquinone without altering the antioxidant function thereof.
  • small changes would include modifications of the methyl group at C5, the methoxy groups at C2 and C3, as well as modifications of the isoprenoid side chain at C6.
  • these small changes would not significantly adversely alter the functional properties of the ubiquinone. More specifically, the modifications at one or more of these positions will not adversely affect the oxidation- reduction properties of the modified ubiquinone so as to significantly diminish its anti-oxidant characteristics.
  • such small changes in the isoprenoid side chain will not adversely affect the lipophilic characteristics of the modified ubiquinone.
  • Examples of small changes include modification or substitution of the C5 methyl group, the C2 and C3 methoxy groups, or the isoprenoid side chain with additional substituents such as lower alkyl groups having from one to six carbon including branched, cyclic and straight chain alkyl groups; aryl substituents including phenyl and substituted phenyl substituents; aralkyl substituents including benzyl and tolyl substituents; halogen substituents including fluoro substituents; oxygen substituents including hydroxy, lower alkoxy, ether, and ester substituents; nitrogen substituents including amino and amido substituents; sulfur substituents including thiol, thioether, and thioester substituents.
  • substituents such as lower alkyl groups having from one to six carbon including branched, cyclic and straight chain alkyl groups; aryl substituents including phenyl and substituted phenyl substituents; aralkyl substituents including
  • ubiquinol includes to a reduced form of ubiquinone (also known as “hydroquinone”) represented by the following general formula Z'.
  • ubiquinol like the term “ubiquinone,” encompasses synthetic and naturally occurring ubiquinols and the corresponding ubiquinols having small changes to their structure.
  • the nature of the small changes to the ubiquinol structure are as described above for the ubiquinones of the present invention.
  • the reversible reduction/oxidation shown in the interconversion of formulae 1 and 2 in FIGURE 1 is the natural process involved in redox cycling for electron transport in mitochondria and in the characteristic antioxidant properties of the ubiquinone.
  • Reduction of the quinone functional group of a ubiquinone is achieved chemically using any one of several reagents, including, by way of example, exposure to zinc in acetic acid, sodium borohydride, or lithium aluminum hydride.
  • Reduction of the quinone may be confirmed by any one of several means, including, by way of example, observing a change in solution color from yellow to colorless and by spectroscopic methods including nuclear magnetic resonance spectroscopy. Reverse oxidation can be accomplished by any one of several means, including by way of example, exposure to air.
  • preparation of a ubiquinone prodrug of the present invention starting from a ubiquinol is best conducted under an inert atmosphere, by way of example, an argon or a nitrogen atmosphere.
  • pegylated includes coupling polyethylene glycol (PEG) to a particular molecule.
  • PEG polyethylene glycol
  • some of the water soluble ubiquinone prodrugs of this invention are pegylated CoQlO derivatives. Coupling of a particular PEG to provide a ubiquinone prodrug may be achieved either by direct coupling to a ubiquinol or by coupling through a linker group or spacer group.
  • solubilizing moiety includes a moiety that, when covalently coupled to a ubiquinone (or coupled to a lipophilic moiety to produce a solubilizing agent), increases the water solubility of a ubiquinone (or a solubilizing agent).
  • the solubilizing moiety is coupled through a linking group.
  • linking group includes a moiety that serves to couple the solubilizing moiety to the ubiquinone moiety.
  • a linking group may also serve to couple a targeting moiety to either a solubilizing moiety or a ubiquinone moiety.
  • the linking group results from a chemical reaction that occurs, for example, between a solubilizing (or targeting) moiety and a ubiquinone.
  • the linking group includes a variety of functional groups.
  • the linking group may be an ester formed by reaction of the Cl phenolic hydroxy group of a ubiquinol with a carboxylic acid derivative of a solubilizing moiety.
  • the linking group is cleaved in vivo and results in the release of a ubiquinone.
  • targeting moiety includes a moiety that, when covalently coupled to a ubiquinone or a solubilizing moiety, directs the molecule for uptake into a particular tissue or cell type generally through a receptor-mediated mechanism.
  • a targeting moiety is to enhance processing of a ubiquinone, in particular water soluble forms of CoQlO, or to enhance accumulation into membranes of certain cells.
  • isolatedizing agent includes a lipophilic moiety coupled to a solubilizing moiety which, when combined with a ubiquinone or derivative thereof, provides a ubiquinone delivery composition having increased water solubility.
  • water soluble includes the ability of a ubiquinone prodrug or ubiquinone delivery composition to dissolve in water or other aqueous milieu.
  • a ubiquinone prodrug or ubiquinone delivery composition is considered soluble if it improves the solubility of a ubiquinone in water by about 10 3 to 10 and preferably by about 10 7 times; however, such improvement is not essential.
  • apoptosis includes programmed or apoptotic cell death.
  • apoptosis is the key mechanism associated with homeostatic regulation, a process by which cell death or suicide is naturally or deliberately invoked to produce cell turnover.
  • early stage events such as disruption of the redox potential, activation of certain "death” genes, and exposure to mild toxic insult are part of several different complex mechanisms that ultimately funnel into the common late stage events.
  • late stage events include protein synthesis and activation of magnesium and/or calcium-dependent endonucleases that lead to DNA fragmentation and, ultimately, apoptotic cell death.
  • biological preparation includes an ex vivo cell culture which may be suitable for introduction into a warm-blooded animal.
  • ameliorate or “amelioration” includes an inhibition of apoptosis such that the incidence of apoptosis is lower than that which would otherwise occur under the same or similar (i.e., control) conditions.
  • ischemia includes a temporary blockage of blood flow to a tissue that results oxygen deficiency and often cell death in affected tissues, including by way of example the brain, heart, spinal column, eyes, colon, and kidney.
  • ische ic tissue includes a tissue that results oxygen deficiency and often cell death in affected tissues, including by way of example the brain, heart, spinal column, eyes, colon, and kidney.
  • reperrusion injury refers to cell injury that occurs following restoration in blood flow in an ische ic tissue.
  • treatment includes reducing or alleviating symptoms in a subject, preventing symptoms from worsening or progressing, inhibition or elimination of the causative agent, or prevention of the infection or disorder in a subject who is free therefrom.
  • a disorder is “treated” by partially or wholly remedying the deficiency which causes the deficiency or which makes it more severe.
  • An unbalanced state disorder is “treated” by partially or wholly remedying the imbalance which causes the disorder or which makes it more severe.
  • the subject may be a human patient or other warm-blooded animal.
  • blood-brain barrier refers to the blood-brain barrier made up of brain microvessel endothelial cells characterized by tight intercellular junctions, minimal pinocytic activity, and the absence of fenestra. These characteristics endow these cells with the ability to restrict passage of most small polar blood- borne molecules (e.g., neurotransmitters, including catechoiamines and neuropeptides) and macromolecules (e.g., proteins) from the cerebrovascular circulation to the brain.
  • the blood- brain barrier contains highly active enzyme systems as well, which further enhance the already very effective protective function.
  • the blood-brain barrier is one of the greatest impediments to delivery of pharmaceuticals to the central nervous system.
  • the transport of molecules to the brain is not determined solely by the molecular size but by the permeabilities governed by the specific chemical characteristics of the permeating substance and, additionally, by the presence of receptor-mediated transport mechanisms such as those associated with transferrin, insulin, and catecholamines.
  • receptor-mediated transport mechanisms such as those associated with transferrin, insulin, and catecholamines.
  • One aspect of the present invention provides water soluble ubiquinone prodrugs which revert to a ubiquinone or a derivative thereof under in vivo conditions.
  • the water soluble ubiquinone prodrugs of the present invention are comprised of a ubiquinol coupled to a solubilizing moiety.
  • a water soluble ubiquinone prodrug designed to revert to a ubiquinone under in vivo conditions is provided.
  • a solubilizing moiety is coupled to a ubiquinol at one or both of positions Cl and C4 (i.e., the phenolic hydroxyl groups) of the ubiquinol, forming a water soluble ubiquinone prodrug.
  • These prodrugs are cleaved spontaneously to ubiquinol and then oxidized to ubiquinone under in vivo conditions (see FIGURE 2).
  • the prodrugs of this invention include ubiquinols substituted at position Cl with a solubilizing moiety and having a C4 phenolic hydroxy group, as well as ubiquinols substituted at position C4 with a solubilizing moiety and having a Cl phenolic hydroxy group.
  • the solubilizing moiety is linked to at least one of positions Cl and C4 of a ubiquinol to increase the aqueous solubility of the ubiquinone prodrug. Cleavage of the solubilizing moiety releases the ubiquinone, which represents the oxidized form of the ubiquinol.
  • a ubiquinol linked through these positions to a solubilizing moiety increases the aqueous solubility of a ubiquinone.
  • a solubilizing moiety is coupled directly to a ubiquinol.
  • a solubilizing moiety is coupled to a ubiquinol through a linking group.
  • Such linking groups are used to form prodrugs that are cleaved by in vivo conditions such as, by way of example, pH and enzymatic activity. Suitable prodrugs are cleaved, by way of example, by enzymes such as esterases, oxidases, reductases, peptidases, and demethylases.
  • a cleavable linking group may be selected based on the desired stability of the linkage between a ubiquinol and a solubilizing moiety.
  • Suitable cleavable linking groups include any group that may be cleaved in vivo including, by way of example, an ester, ether, carbamate, or carbonate group (see FIGURE 2).
  • Other suitable cleavable linking groups include polymeric sequences of sugars, amino acids, or nucleic acids (i.e., polysaccharide, polypeptide, nucleic acid sequences) that are cleaved by biological enzymes capable of cleaving these sequences.
  • nucleic acids i.e., polysaccharide, polypeptide, nucleic acid sequences
  • a ubiquinone prodrug of the present invention need not be cleaved directly to ubiquinone. It may require several enzymatic steps for a prodrug to be converted first to a ubiquinol, and then subsequently to a ubiquinone.
  • the nature of the cleavage of a ubiquinone prodrug in vitro may be accomplished by any one of several means, including using a variety of liver homogenates.
  • Evaluation of the physical and biological properties of the ubiquinone prodrugs before and after cleavage may be accomplished by any one of several means, including cyclic voltammetry, UV absorbance spectrophotometry, high pressure liquid chromatography, and mass spectrometry.
  • One aspect of the present invention includes a ubiquinone ester prodrug.
  • This prodrug is readily cleaved by any one of several enzymes, including esterase enzyme present in the blood serum. Due to the nature of the ubiquinol, a ubiquinone ester prodrug is a readily cleaved derivative and, thus, is particularly suited for cases where a quick release of a ubiquinone is desired.
  • a ubiquinone ester prodrug may be formed using any one of several means, including using an esterifying agent such as, by way of example, an acid chloride, an activated acid ester (e.g., N-hydroxysuccinimide and tetrafiuorophenyl esters), and an anhydride.
  • ubiquinone carbonate prodrug and a ubiquinone carbamate prodrug.
  • These prodrugs are acid sensitive and are be cleaved in vivo in the endosomes and lysosomes.
  • these ubiquinone prodrugs are endocytosed by components of the reticular endothelial system (e.g., Kupfer cells) or hepatic parenchyma cells and subsequently processed through intravesicular pathways of the cells.
  • polar cells such as liver parenchyma cells
  • one pole of the cell may be responsible for uptake of the ubiquinone.
  • the resulting ubiquinone associates with LDL cholesterol, low density lipoprotein cholesterol complex, for transport in the blood serum.
  • Ubiquinone carbonate prodrugs may be formed using any one of several means including the use of a carbonate forming agent such as, by way of example, a carbonyl chloride.
  • a carbonate forming agent such as, by way of example, a carbonyl chloride.
  • reaction of a carbonyl chloride of a ubiquinol with an alcohol form of a solubilizing moiety produces a carbonate linkage.
  • reaction of a ubiquinol with a carbonyl chloride of a solubilizing moiety similarly provides a carbonate linkage.
  • Ubiquinone carbamate prodrugs may be formed using any one of several means including the use of a carbamate forming agent such as, by way of example, an isocyanate reagent. The preparation of representative ubiquinone prodrugs having a carbamate linking group is described in Example 11.
  • Yet another aspect of the present invention includes a ubiquinone ether prodrug.
  • Ubiquinone ether prodrugs are formed by any one of several means including the use of an alkylating agent such as an alkyl halide, a benzylic halide, an alkyl sulfonate (e.g., tosylates, thesylates, triflates), and a benzylic sulfonate.
  • an alkylating agent such as an alkyl halide, a benzylic halide, an alkyl sulfonate (e.g., tosylates, thesylates, triflates), and a benzylic sulfonate.
  • an alkylating agent such as an alkyl halide, a benzylic halide, an alkyl sulfonate (e.g., tosylates, thesylates, triflates), and a benzylic sulfonate.
  • spacer group containing one of these functional groups is reacted with a ubiquinol and, in a subsequent step, a solubilizing moiety (or targeting moiety) is coupled to the spacer group on the modified ubiquinol.
  • spacer groups are bifunctional reagents capable of reaction with, for example, both a ubiquinol and a solubilizing or targeting agent.
  • Suitable spacer groups are known in the art and include dicarboxylic acid groups such as subaric and sebacic acids, and amino acids such as 4-aminobutyric acid, among others.
  • An advantage of the spacer group is to provide additional length between, for example, the solubilizing group and the ubiquinol to relieve steric congestion that might otherwise impede coupling to or cleavage from the solubilizing or targeting moiety to the ubiquinol.
  • a solubilizing moiety or targeting moiety may be coupled directly to a ubiquinone through a linking group or a spacer group as long as the desired characteristics of the molecule are not compromised by the additional atoms.
  • a suitable solubilizing moiety includes any hydrophilic moiety which increases the solubility of the prodrug over that of a native ubiquinone and is cleavable, or is coupled to ubiquinone by a linker cleavable, in vivo.
  • the solubility of the compound may be determined by "Handbook of Solubility Parameters and Other Cohesion Parameters" by AFM Benton, CRC Press, 1983.
  • Hydrophilic moieties are polar moieties which may be either charged (i.e., ionic) or electronically neutral. It should be appreciated that, if more than one solubilizing moiety is utilized, the hydrophilicity of the moieties may be additive.
  • Suitable hydrophilic moieties include electronically neutral solubilizing moieties. These moieties contain one or more polar functional groups (i.e., groups which contain atoms of differing electronegativities such as organic compounds containing nitrogen, oxygen, and sulfur) that increase their hydrophilicity. Typically, these neutral solubilizing moieties contain functional groups capable of forming hydrogen bonds with water. Such hydrogen bonding groups include ether (-O-), hydroxy (-OH), amino (-NR2, -NHR, -NH2), and thioether (-S-) and thiol (-SH) groups.
  • polar functional groups which may serve as hydrophilic moieties include carbonyl containing groups such as acids, esters, amides, ketones, and aldehydes. Moieties which contain multiple polar functional groups are more hydrophilic than those moieties which contain a single polar functional group.
  • Suitable moieties include, by way of example, polyalcohol, polyamine, polyether and polypeptide moieties.
  • Polyalcohol moieties include, by way of example, glycols, glycerols, and polysaccharides including glucose, fructose, galactose, idose, inositol, mannose, tagatose, N-methylglucamine, and dextran moieties.
  • Polyether moieties include, by way of example, polyethylene glycol, ethoxyethanol, and ethoxyethoxyethanol moieties.
  • Polyamine moieties include, by way of example, spermine and spermidine moieties.
  • Polypeptide moieties include peptides that contain electronically neutral amino acid residues.
  • a solubilizing moiety is a polyethylene glycol.
  • suitable polyethylene glycols include those with a molecular weight in the range of about 350 to about 6000; typically with a molecular weight in the range of about 600 to about 3400; and preferably in the range of about 1500 to about 2500 and, even more preferably, selected from polyethylene glycol 2000, polyethylene glycol 3400, and polyethylene glycol 5000 (Aldrich Chemical Co., Milwaukee, Wisconsin and Shearwater Polymers, Inc., Huntsville, AL).
  • the polyethylene glycols (PEGs) noted above are designated by their approximate molecular weights (e.g., about 1500), and more specifically their approximate molecular weight ranges (e.g., about 1500 to about 2500).
  • Commercially available PEGs are available as mixtures of PEGs having designated average molecular weights (e.g., polyethylene glycol 20,243-6 from Aldrich Chemical Co. has average M, ca. 1,500).
  • These PEGs are available as mixtures having average molecular weights due to the polymeric syntheses from which the PEGs are prepared.
  • the present invention includes PEG mixtures having designated average molecular weights, and also includes PEG and PEG containing compounds that are homogeneous and have discrete molecular weights.
  • Suitable electronically charged solubilizing moieties include those moieties which become either formally negatively or positively charged in water. Accordingly, electronically charged solubilizing moieties include anionic and cationic moieties, polyanionic and polycationic moieties, and moieties that contain both anionic and cationic species. Suitable negatively charged moieties include acid anions resulting from the dissociation of acids in water. For example, carboxylic acids (-CO2H) dissociate to form negatively charged carboxylate ions (-CO2”) (pH greater than 5).
  • amines (-NR2, -NHR, -NH2, where R is an alkyl or aryl group) become ammonium ions (-NHR2 + , -NH2R + , -NH3 + ), all of which are highly water solubilizing moieties.
  • Quaternary ammonium moieties (-NR3 + ) are extremely water solubilizing (at all pHs).
  • Suitable electronically charged solubilizing moieties include polypeptides containing cationic, or anionic, or both cationic and anionic amino acid residues.
  • Other polycationic moieties include, for example, spermine, spermidine, and polylysine moieties.
  • Water solubility of a ubiquinone prodrug may be evaluated by any one of several means, including, by way of example, simply combining the derivatives with an aqueous medium and observing the solubility at various temperatures.
  • the water solubility is determined by the components of the prodrug, namely, the lipophilic nature of the particular ubiquinone and the hydrophilic nature of the particular PEG solubilizing moiety.
  • the longer the terpenoid side chain of a ubiquinone the greater is its lipophilicity thus requiring a PEG solubilizing agent having a greater molecular weight.
  • CoQ2 i.e., ubiquinone ⁇ O
  • CoQlO is best water solubilized by a PEG solubilizing moiety having a molecular weight of 1500 or greater.
  • the water solubility of a particular ubiquinone prodrug is controlled by the nature of the solubilizing moiety.
  • a ubiquinone prodrug containing greater than about 10% by weight PEG 5000 is highly hygroscopic and forms a gel.
  • a ubiquinone prodrug that contains less than about 10% by weight PEG 5000 forms a solution. Either of these prodrugs can be further diluted with water to provide an aqueous solution of the prodrug.
  • gel formation does not occur until the weight percent of the PEG is greater than 10%.
  • water solubihty may be ascertained by dissolving the derivative in water, stirring the solution and allowing the solution to stand at room temperature for about 24 hours. The solution is then centrifuged and the resultant aqueous layer analyzed using high pressure liquid chromatography (HPLC).
  • HPLC analysis may be conducted isocratically using acetonitrile as the solvent on a LiChrospher 100, C-18 column (5 ⁇ M, 125 x 4 mm) using a flow rate of 2 rnlJmin. Under these conditions, the coenzyme QlO-containing product has a retention time of 7.6 min.
  • the quantitation of the coenzyme QiQ-containing solution may be accomplished by HPLC using UV detection at about 254 nm.
  • an aqueous solution of a coenzyme Q10 derivative is prepared and analyzed by HPLC as described above.
  • a series of aqueous solutions of coenzyme Q10 derivatives of known concentration are prepared and analyzed by HPLC.
  • the results of these HPLC analyses are then used to construct a standard curve where the concentration of the coenzyme Q10 standard is plotted against the HPLC signal for the standard. Once such a standard curve has been constructed, aqueous solutions of coenzyme Q10 derivatives may be similarly analyzed and the concentration of the derivative in the solution determined.
  • the water solubility of a ubiquinone prodrug may be determined directly by absorbance spectroscopy. Briefly, a known amount of a ubiquinone prodrug is dissolved in a known amount of water to provide an aqueous solution of known concentration (e.g., 10 mg prodrug/ 10 mL water). The absorbance of this solution (or dilutions of the solution) is then measured by a UV absorbance spectrophotometer. The absorbance of the solution of known concentration provides the prodrug' s absorptivity (e.g., a 10 mg/10 mL solution produces an absorbance of 0.95).
  • a known amount of a ubiquinone prodrug is dissolved in a known amount of water to provide an aqueous solution of known concentration (e.g., 10 mg prodrug/ 10 mL water).
  • the absorbance of this solution is then measured by a UV absorbance spectrophotometer.
  • the absorbance of the solution of known concentration provides
  • the concentration (or the amount of prodrug in the solution) of subsequent aqueous solutions of the prodrug may be determined by measuring the absorbance of the solution.
  • a ubiquinone prodrug may be then cleaved to a ubiquinol, using any of the in vivo conditions outlined above, then the ubiquinol may be allowed to revert to a ubiquinone and the absorptivity measured in solution. The absorptivity may then be compared to the standard created above.
  • a ubiquinone (50) is used to form a ubiquinone prodrug of the present invention.
  • a ubiquinone (50) is coupled to a polyether solubilizing moiety such as a polyethylene glycol with a molecular weight in the range of about 350 to 6000; typically with a molecular weight in the range of about 600 to about 3400; and preferably in the range of about 1500 to about 2500 and, even more preferably, selected from polyethylene glycol 2000, polyethylene glycol 3400, and polyethylene glycol 5000.
  • ubiquinone prodrugs detailed above are additionally coupled to a targeting moiety.
  • the targeting moiety is preferably coupled to the ubiquinone prodrug via a solubilizing moiety.
  • Suitable targeting moieties include any moiety which will direct the ubiquinone prodrug to a desired cell surface receptor.
  • a targeting moiety has an affinity for a cell surface receptor of within 100-fold, and more preferably, within 10-fold, of the affinity of the natural ligand for the receptor. Covalent attachment of a targeting moiety should not significantly hinder the ability of the targeting moiety to specifically bind the cell surface receptor. Other moieties may also be present, so long as they do not interfere with either the targeting or the solubilizing moieties.
  • Optimal attachment of the targeting moieties to ubiquinone may be determined by comparing the affinity of binding of the ubiquinone prodrug with a free targeting moiety in assays of inhibition of binding. This, and other suitable techniques, are described in detail in Sambrook et al., Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, 1989.
  • the targeting moiety is covalently attached to the ubiquinone prodrug by any suitable means known in the art, including direct covalent linkage, through a solubilizing moiety, or through the use of a linking group.
  • the targeting moiety is coupled to the solubilizing moiety, or alternatively, to one of the Cl or C4 positions (i.e., the phenolic hydroxy groups) of the ubiquinol either directly or through the use of a linking group.
  • Coupling of a targeting moiety through a solubilizing moiety is preferably of a nature which resists cleavage by the enzymatic and low pH conditions normally encountered in vivo.
  • Coupling of a targeting moiety directly to a ubiquinone or ubiquinone prodrug is preferably of a nature which does not resist cleavage in vivo.
  • the ability to resist cleavage may be detected by any means known in the art, including exposing the ubiquinone to enzymes at low pH and measuring release of the targeting or solubilizing moiety using techniques known in the art.
  • a preferred linking group is an ether.
  • Suitable targeting moieties include ligands such as proteins, peptides, and non- proteinaceous molecules.
  • suitable targeting moieties include antibody and antibody fragments; peptides such as bombesin, gastrin-releasing peptide, cell adhesion peptides, substance P, neuromedin-B, neuromedin-C and metenkephalin; hormones, including EGF, alpha- and beta-TGF, estradiol, neurotensin, melanocyte stimulating hormone, follicle stimulating hormone, luteinizing hormone, and human growth hormone; proteins or peptides corresponding to ligands for known cell surface receptors, including low density lipoproteins, transferrin, vitamin B.
  • targeting moieties that retain the ability to specifically bind to a cell surface receptor are suitable targeting moieties.
  • a targeting moiety is a ligand directed to a receptor selected from LDL receptors, polyamine receptors, insulin receptors, and alpha-2- macroglobulin receptors.
  • a targeting moiety is selected which directs the ubiquinone prodrug to the liver.
  • targeting moieties include, by way of example, targeting moieties which direct binding to an asialoglycoprotein receptor, including triantennary galactosides and arabinogalactan.
  • a targeting moiety is a lactosylated, galactosylated, mannosylated or glycosylated dextran-based ligand for lectin-like carbohydrate receptors such as the asialoglycoprotein receptor or galactose receptor.
  • a targeting moiety is directed to the blood-brain barrier.
  • Suitable targeting moieties for this purpose include, by way of example, ligands directed to receptors on cells which mediate blood-brain barrier transport, such as endothelial cells.
  • receptors include, by way of example, transferrin receptors, and low density lipoprotein receptors.
  • the targeting characteristics of a ubiquinone prodrug may be ascertained by any one of several means including, by way of example, utilizing radiolabeled derivatives to track pharmacokinetics of targeted molecules (see, e.g., Tomono et al., Int'l J. of Clin. Pharm.. Therapy and Toxicology 24(10*536-541. 1986).
  • another aspect of the present invention provides a ubiquinone delivery composition.
  • One embodiment of the present invention provides a ubiquinone delivery composition comprised of a solubilizing agent and a ubiquinone.
  • Another embodiment provides a ubiquinone delivery composition comprised of a ubiquinone prodrug, a solubilizing agent, and a ubiquinone.
  • Yet another embodiment provides a ubiquinone delivery composition comprised of a ubiquinone prodrug and a ubiquinone.
  • Suitable solubilizing agents include compounds having a lipophilic portion or moiety and a solubilizing portion or moiety such that, when combined with a ubiquinone or derivative thereof, a water soluble composition is formed.
  • the solubilizing moiety of the solubilizing agent must be sufficiently hydrophilic to solubilize the solubilizing agent and associated ubiquinone or derivative thereof in aqueous medium.
  • the lipophilic moiety must be capable of associating with the Upophilic portion of a ubiquinone or derivative thereof.
  • Suitable Upophilic moieties include Upids and phosphoUpids, including by way of example, fatty acids, fatty esters, and fatty alcohols.
  • Suitable fatty acids include branched and straight chain fatty acids having from about 8 carbons to about 30 carbons including saturated and unsaturated fatty acids.
  • Representative fatty acids include linoleic, linolenic, and oleic acids.
  • Representative fatty alcohols also include branched and straight chain fatty alcohols having from about 8 carbons to about 30 carbons including saturated and unsaturated fatty alcohols.
  • Suitable fatty alcohols include sterols.
  • a preferable sterol is cholesterol.
  • Lipophilic moieties may be comprised of more than one fatty acid or a combination of a variety of lipophilic moieties (e.g., Unoleic-Unoleic-polyethylene glycol).
  • suitable solubilizing moieties include the electronically neutral solubilizing moieties described above.
  • Suitable solubilizing agents include lipophilic moieties comprising fatty alcohols, fatty esters, and fatty acids coupled to electronically neutral solubilizing moieties such as PEGs, polysaccharides, and polypeptides.
  • a solubilizing moiety may be coupled to a lipophilic moiety either covalently or through a lipophilic linking agent.
  • a lipophilic moiety either covalently or through a lipophilic linking agent.
  • Any one of several suitable homo- or hetero-bifunctional lipophilic linking agents may be utilized including, by way of example, suberic acid, succinic acid, and sebacic acid.
  • Covalent coupling of the solubilizing moiety and the Upophilic moiety is of a nature which allows cleavage in the enzymatic and low pH conditions normally encountered in vivo. The ability to resist cleavage may be detected by any means known in the art, including exposing the solubilizing agent to enzymes at low pH and measuring release of the solubilizing or lipophilic moiety using techniques known in the art.
  • Covalent coupling of the solubilizing moiety and the lipophilic moiety should not significantly hinder the hydrophilic character of the solubilizing moiety.
  • Other moieties may also be present, so long as they do not interfere with the characteristics of either the solubilizing or the lipophilic moieties.
  • Optimal attachment of the two moieties may be determined by comparing the solubihty of the various solubilizing agents thus produced. Solubihty can be determined by the methods described in detail above.
  • a solubilizing agent is comprised of a cholesterol coupled to any one of the above-noted electronically neutral solubiUzing moieties.
  • a solubilizing agent is comprised of a cholesterol pegylated through a sebacic acid linker.
  • a solubiUzing agent and a ubiquinone (or derivative thereof) are combined under suitable conditions and for a time sufficient to produce a water soluble ubiquinone delivery composition.
  • a ubiquinone and a solubilizing agent are dissolved in an organic solvent, water is added, the liquid is evaporated to remove organic solvent, and water or a buffered aqueous solution, e.g., phosphate buffered saline, is added.
  • the organic solvent may be any one of several water miscible solvents including alcohols such as methanol, ethanol, and propanol, dimethylsulfoxide, and, preferably, tetrahydrofuran.
  • the liquid may be evaporated at ambient temperature by any one of several means, including vacuum or a stream of an inert gas.
  • the molar ratio of ubiquinone to solubiUzing agent generally should be in the range of about 1:2 to about 1:10; preferably, the molar ratio is about 1:3.
  • the ubiquinone/solubilizing agent formulation is dissolved in water to a required concentration of ubiquinone.
  • the ubiquinone content may be ascertained by any one of several means including spectrophotometricaUy foUowing dilution in ethanol from the extinction coefficient at 275 nm of 14,200.
  • Another aspect of the present invention provides for the administration of a ubiquinone, via a ubiquinone prodrug or a ubiquinone deUvery composition, to a warm- blooded animal or a biological preparation in an amount sufficient to ameUorate apoptotic cell death.
  • warm-blooded animal includes human.
  • apoptosis is associated with, among other causes, oxidative stress resulting from the production of free radicals.
  • Free radicals or oxidants such as superoxide radicals, hydrogen peroxides, hydroxyl radicals and Upid peroxides, are intimately intertwined in the etiology of many disease states (Saltman, Semin.
  • Another class of free radical scavengers integrate into the Upid membranes, thus maintaining a relatively constant presence in the cell.
  • This class includes Upophilic free radical scavengers, by way of example, the antioxidants alpha-tocopherol (Vitamin E) and CoQlO.
  • CoQlO has demonstrated its antioxidant effect on emulsions of arachadonic acid and isolated mitochondrial membranes subjected to peroxidative insult (MeUors and Tappei, J. Biol. Chem. 211:4353, 1966; Battino et al., Biomedical and Clinical Aspects of Coenzvme O. Folkers et al. (eds.), Elsevier, Vol. 6, p. 181-190, 1991).
  • Ubiquinones are particularly weU suited for treating apoptosis.
  • ubiquinones are superior antioxidants.
  • CoQlO is oxidized before alpha- tocopherol or carotenoids in disarming the toxic products of low density Upoproteins (LDL).
  • LDL low density Upoproteins
  • the concentrations of the hydroperoxides of phosphoUpids and cholesterol begin to increase once the available CoQlO has been consumed, despite the constant presence of alpha-tocopherol and carotenoid concentrations (Stocker et al., Proc. Natl. Acad. Sci. U.S.A. £8:1646, 1991).
  • ubiquinones regenerate other antioxidants to their active form by donating electrons. This is exemplified by the foUowing reaction with alpha-tocopherol: tocopherol-O + C0QH2 ⁇ tocopherol-OH + CoQH
  • This electron donating feature (beUeved to be due to the favorable redox potential of ubiquinol, a ubiquinone intermediate) helps maintain high levels of antioxidants within a variety of compartments within the cell.
  • Ubiquinones are essential for supplying the cell with energy.
  • Ubiquinones play an integral role in transporting electrons in the respiratory chain by coupling the transfer and translocation of electrons through the hydrocarbon osmotic carbon domain of the inner mitochondrial membranes.
  • the location of ubiquinones within the electron transport chain is between the flavoproteins and cytochrome _-_l complex.
  • Ubiquinone functions as a redox carrier between the two fiavin-FeS dehydrogenases and the cytochromes b and the later cytochrome ci.
  • ubiquinone has some regulatory effects on succinate dehydrogenase (Rossi et al., Eur. J. Biochem.
  • ubiquinones With regard to apoptosis, an abundant energy supply is necessary to synthesize molecules involved in and carry out ceUular repair caused by various indicators of apoptosis. Since a damaged cell is a signal for the apoptotic process, repair with non-lethal damage can offset the apoptotic cascade. These three characteristics render ubiquinones particularly suitable for use in ameUoration of apoptosis in warm-blooded animals, and biological preparations. However, as noted above, ubiquinones are poorly soluble in aqueous solutions, and as a result are poorly assimilated in vivo. Consequently, the limited bioavailabUity of ubiquinones decreases their utility as therapeutic agents.
  • the ubiquinone prodrugs and delivery compositions are utiUzed for the treatment of apoptosis associated with ischemia.
  • FoUowing ischemia there is a significant increase in free radical production.
  • the initial damage to neuronal tissue is thought to result from the peroxidation products with subsequent damage from secondary radicals.
  • Eventually the metaboUc and synthetic pathways are damaged to such an extent that the ceU cannot make sufficient repairs and dies.
  • the invention includes ubiquinone prodrugs and ubiquinone delivery compositions, which pass through the blood- brain barrier and decrease or prevent ceU damage during or after ischemia by decreasing or preventing ATP depletion, thus stabilizing the perturbed redox status of the ceUs and tissue.
  • ischemic injuries may occur to the central nervous system as a result of conditions such as stroke, cerebral pressure, cerebral infarction, physical trauma, such as head and spinal injuries, oxygen deprivation, cerebral hemorrhage, such as arachnoid hemorrhage and subdural hemorrhage, and chemical trauma.
  • Ischemic injuries may also occur as a result of cardiovascular disorders such as angina infarction, cardiac arrest, congestive heart failure, cardiac arrhythmias, arterial hypertension, arteriosclerosis, occlusion of the aorta, cardiomyopathy and transient ischemic attacks.
  • cardiovascular disorders such as angina infarction, cardiac arrest, congestive heart failure, cardiac arrhythmias, arterial hypertension, arteriosclerosis, occlusion of the aorta, cardiomyopathy and transient ischemic attacks.
  • Other disorders which may result in ischemic injury include reanastomosis, frostbite, coUc, and founder.
  • ubiquinone prodrugs and deUvery compositions are administered to treat disorder or damage associated with exposure to high pressure oxygen or oxygen radical enriched environments.
  • such conditions include ocular damage in babies placed on high oxygen respirators, drug and alcohol induced damage to the CNS or other organs, and damage resulting from ionizing radiation or photo-oxidation.
  • ubiquinone prodrugs and deUvery compositions are administered to ameUorate apoptosis in a warm-blooded animal suffering from, or susceptible to, a viral disorder.
  • ubiquinone prodrugs and deUvery compositions are administered to a biological preparation to ameUorate apoptosis in a warm-blooded animal suffering from, or susceptible to, a viral disorder.
  • viral disorders include, by way of example, AIDS (Fauci, Science 26.2:1011, 1993; Ameisen, Immunol. Today 13:388. 1992; Gorla et al., AIDS Research and Human Retroviruses 10(9):1097, 1994) and hepatitis.
  • the etiology of HTV infection involves the gradual loss of T-ceU function characterized by the failure of T-ceUs to proliferate in response to various mitogens and recall antigens. Ubiquinones play a changing role over the course of the disease.
  • lymphocytes preferably T- h/mphocytes
  • an assay which utilizes detection of DNA strand breaks in apoptotic cells using the terminal deoxynucleotidyl transferase method (e.g., Gorczyca et al., Cancer Research 53: 1945, 1993). Briefly, a blood sample is drawn by vein puncture and white blood ceUs are isolated by FicoU-Hypaque centr ⁇ ugation.
  • ceUs are washed in phosphate buffered saline and T-ceUs are then purified using a variety of techniques available, such as ceU sorting by FACS or by affinity chromatography in which T-ceUs are bound by specific antibodies to a matrix and non-T-ceUs are eluted through the column. Next, the bound ceUs are eluted and checked for purity by fluorescent labeled antibodies on a sample of the population. For detection of apoptosis, ceUs are ethanol fixed and resuspended in a sodium cacodylate buffer. Biotinylated nucleosides (e.g., biotin-16-dUTP) are added to the fixed ceUs along with avidin-FllC.
  • biotinylated nucleosides e.g., biotin-16-dUTP
  • lymphocytes can be activated with mitogens (e.g., PHA), bacterial superantigens, or anti-CD3 monoclonal antibodies before the fixation process.
  • mitogens e.g., PHA
  • bacterial superantigens e.g., bacterial superantigens
  • anti-CD3 monoclonal antibodies e.g., anti-CD3 monoclonal antibodies
  • ubiquinone prodrugs and deUvery compositions may be administered to ameUorate apoptosis in a warm-blooded animal suffering from, or susceptible to, a neurodegenerative disorder.
  • ubiquinone prodrugs and deUvery compositions are administered to a biological preparation to ameUorate apoptosis in a warm-blooded animal suffering from, or susceptible to, a neurodegenerative disorder.
  • the association of apoptosis with a particular neurodegenerative disorder may be determined by estabUshing, for example, indicators of energetic defects using magnetic resonance imaging (MRI) and other standard imaging methods.
  • MRI magnetic resonance imaging
  • Such neurodegenerative disorders include, by way of example, Parkinson's disease (Beal et al., TINS 16(4): 125, 1993 Bloe et al., J. Neural. Sci. 97:293 1990; Brennan et al., J. Neurochem. 44:1948, 1985) Alzheimer's disease (Beal et al., TINS 16 4):125, 1993; Beal, Ann. Neurol. ⁇ :119, 1992) Huntington's disease (Beal et al., TINS 16(4): 125, 1993; Bloem et al., J. Neurol. Sci. 97:293 1990; Brennan et al., J. Neurochem.
  • ubiquinone prodrugs or deUvery compositions may be administered to ameUorate apoptosis in a warm-blooded animal suffering from, or susceptible to, a late stage cardiovascular disease.
  • the association of apoptosis with a particular late stage cardiovascular disease may be determined by any one of several means, including, by way of example, blood chemistry profiles and image analysis foUowing injectable dyes.
  • Such cardiovascular diseases include, by way of example, acute (intravenous) therapy for myocardial infarction, in which ubiquinones decrease apoptosis of cardiac cells foUowing reperfusion.
  • ubiquinone prodrugs and deUvery compositions may be administered to ameUorate apoptosis in warm-blooded animals suffering arterial intima thickening associated with arteriosclerotic lesions (Schwartz et al., Diabetes Care 15: 1156, 1992; Bjorkerun et al., Arterioscler. Thromb. 14:644, 1994).
  • the ubiquinones are administered in the treatment of arteriosclerosis and nonarteriosclerotic conditions resulting from, in part, progressive intimal thickening with age and balloon angioplasty.
  • ubiquinones are stereotacticaUy deUvered to the lesion either during or immediately foUowing baUoon angioplasty.
  • ubiquinone prodrugs or deUvery compositions may be administered to ameUorate apoptosis in a warm-blooded animal suffering from or susceptible to inflammatory joint disorders.
  • the association of apoptosis to a particular inflammatory joint disorder may be estabUshed by measurement of serum glutamic oxaloacetic transaminase (SGOT) levels, x-ray analysis of infected joints, 99m Tc gamma scintigraphic imaging, arthritis score, measurement of plasma superoxidedismutase activity, and mitogenic and phagocytic responses of peripheral blood leukocytes (lvfiesel and Haas, Inflammation 17(5):595, 1993). Further evidence of inflammation may be obtained by NMR and depletion of key antioxidants within the synovial fluid (Fairburnet al., CUn Sci. £_(6):6570, 1992).
  • SGOT serum glutamic oxaloacetic transaminase
  • RA rheumatoid arthritis
  • cytokines activated by a variety of cytokines are induced to release their cytotoxic contents (NO, O2, H 2 O 2 ).
  • NO, O2, H 2 O 2 cytotoxic contents
  • free radicals or oxidants destroy healthy tissues at the site of inflammation (HeUovaara et al., Ann. Rhem. Pis. 53(1):51, 1994).
  • ubiquinone prodrugs or deUvery compositions may be administered to ameUorate apoptosis in a warm-blooded animal which has been subjected to injury.
  • injury refers to ceUular or tissue injuries caused by physical or chemical means and, which may, ultimately result in ceU death.
  • injuries include, by way of example, ischemia, reperfusion, muscular degeneration, cataracts, hepatotoxicity, pancreatitis, renal injury, lung insults, brain trauma, toxic damage to Uver, angina and cerebral infarction, chemotherapeutic tissue damage and accelerated aging (Linnik et al., Stroke 24(121:2002. 1993).
  • ubiquinone prodrugs or deUvery compositions may be administered to ameliorate apoptosis in a warm-blooded animal which has been administered therapeutics which generally result in oxidative stress.
  • Therapeutics which cause oxidative stress may be identified by TBARS or SGOT levels as described above.
  • Such therapeutics include, by way of example, AZT, anthracycUns, bleomycin, procarbazine, vincristin cyclophosphamide, and mitomycin-c.
  • the ubiquinone prodrugs and compositions of this invention may be administered to ameUorate the toxicity of chemotherapeutic agents such as adriamycin and treat periodontal disease.
  • the ubiquinone prodrugs and compositions may also be administered in combination with other therapeutic agents such as captopril, carnitine, tocopherol and its derivatives, and nicotinamide.
  • the ubiquinone prodrugs and compositions of this invention may be administered in drinking water.
  • the ubiquinone prodrugs and compositions of the present invention are administered in a therapeutically effective dose. A therapeutically effective dose may be determined by in vitro experiment foUowed by in vivo studies.
  • suitable dosages should normally be sufficient to raise plasma values of the ubiquinone to at least this level and, preferably, between 1 to 5 times normal. Such dosages would generally be in the range of about 10 to 400 mg of CoQlO per day; typically be in the range of about 25 to 150, and preferably be in the range of about 30 to 100.
  • dosage will depend on the bioavailability of CoQlO achieved by a particular deUvery system.
  • the ubiquinone prodrugs and compositions of the present invention are formulated into a human or animal pharmaceutical formulation, and incorporated in an admixture with a pharmaceutical carrier and/or diluent according to conventional pharmaceutical techniques.
  • the carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., intravenous, oral, topical, aerosol, inhalant, parenteral or spinal injection.
  • the ubiquinone prodrugs and compositions are useful in the manufacture of medicaments for treating apoptosis.
  • any of the usual pharmaceutical medium can be employed such as, for example, water, glucose, oils, alcohols, flavoring agents, preservatives, coloring agents, or carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like.
  • the aqueous solution may then be inserted, by any one of several suitable means including injection, into a suitable capsule, including, by way of example, a gel capsule, for oral administration.
  • the carrier will usually comprise sterile water, though other ingredients, for example, for preservative purposes may be included.
  • injectable suspensions may also be prepared, in which case appropriate Uquid carriers such as suspending agents, pH adjusting agents, isotonicity adjusting agents and the like may be employed.
  • the first method is based on increasing capUlary permeability by osmoticaUy induced shrinkage of the endotheUal ceUs which cause the widening of the interceUular-type junctions.
  • the osmotic load is generaUy a hyperosmotic water-soluble agent such as mannitol or arabinose.
  • a transfemoral catheter is introduced into the internal carotid or vertebral artery and 150-300 mL infusion of 25% mannitol is administered at 6-10 mg/sec for thirty seconds.
  • the intravenous infusion of the compounds of the present invention is begun approximately 5-7 minutes before the mannitol infusion and is continued for fifteen minutes.
  • the transfemoral catheter is removed and the patient observed for 24-48 hours.
  • a less disruptive technique that allows enhanced drug deUvery to the brain includes increasing the UpophiUcity of the drug.
  • This may be accompUshed using any one of several means including, by way of example, the water soluble ubiquinone prodrugs which are cleaved to ubiquinone after passing the blood-brain barrier.
  • these prodrugs are targeted to carrier/receptor systems present at the blood-brain barrier (passive drug targeting).
  • these prodrugs are targeted to use upregulated transport systems at the blood-brain barrier in disease states (active drug targeting).
  • a ubiquinone prodrug may be targeted for the hexose transport system, the monocarboxylic acid transporter, neutral, basic and acidic amino acid transporters, nucleoside transporters, thiamine transporter and thyroid (T3) transport system.
  • An example of carrier-mediated transport is L-dopa which is transported into the CNS via the neutral amino acid transporter and is then decarboxylated to yield dopamine, the active moiety.
  • ubiquinones can be coupled to a variety of carrier molecules including glucose lactate phenylalanine, lysine, glutamate choline thiamine, a purine or amine.
  • the water soluble ubiquinone derivatives of this invention include ubiquinone prodrugs that serve as effective deUvery vehicles for ubiquinones such as CoQlO.
  • the ubiquinone prodrugs are readily formulated as aqueous solutions having high effective ubiquinone concentrations, and are thus ideal for intravenous administration. Accordingly, the ubiquinone prodrugs of this invention provide a solution to the difficulties associated with administrative routes typically required for the administration of the poorly water soluble ubiquinones including CoQlO.
  • the ubiquinone prodrugs of this invention are readily transported throughout the body of a warm ⁇ blooded animal and furthermore may be targeted to specific sites and tissues.
  • the facile transport of the ubiquinone prodrugs enables deUvery to various tissue sites including the brain.
  • the foUowing examples are provided by way of iUustration, and not by way of limitation.
  • This example illustrates the effect of administering CoQlO to CCRF-CEM cells (a T ceU line) exposed to H 2 O 2 , a molecule capable of inducing oxidative damage and, ultimately, apoptosis in ceU lines.
  • CoQlO is administered using a representative ubiquinone composition of the present invention.
  • Other ubiquinones and ubiquinone prodrugs of this invention may be similarly administered.
  • CCRF-CEM cells a human T-ceU line
  • three different samples of CCRF-CEM cells were prepared by culturing a 2 mL volume of the ceUs (0.8 X 10*) in: (1) RPlvfl 1640 medium and 20 uM CoQlO in water soluble cholesterol (polyoxyethanyl-cholesteryl sebacate, Sigma Chemical Co., St. Louis, MO); (2) RPMI 1640 medium and 50 uM CoQlO in water soluble cholesterol; and (3) RPMI 1640 medium and water soluble cholesterol.
  • the samples were cultured for five days in plastic microtiter plates.
  • This example illustrates the effect of administering CoQlO to the undifferentiated neuronal ceU line PC 12 (ATCC Accession Number 1721) exposed to H 2 O 2 .
  • Undifferentiated PC 12 ceUs have many of the characteristics of fully differentiated neuronal cells and thus appropriately model neuronal ceU apoptosis.
  • CoQlO is administered using a representative ubiquinone composition of the present invention.
  • Other ubiquinones and ubiquinone prodrugs of this invention may be similarly administered.
  • normal undifferentiated PC12 ceUs 0.5X10 6
  • the first group (I) cells were treated for 2 h with 100 uM H 2 O 2 washed and treated with fresh medium. At various time points, ceUs were assessed for cell death by trypan blue dye exclusion using standard techniques.
  • ceUs were pretreated for 2 days with solvent and a tetrahydrofuran/water soluble cholesterol/low density Upoprotein (THF/chol LDL) mixture foUowed by a 2 h treatment with 100 uM H 2 O 2 . Next the ceUs were washed and fresh medium added for an additional 48 h incubation.
  • THF/chol LDL tetrahydrofuran/water soluble cholesterol/low density Upoprotein
  • ceUs were pretreated for 2 days with 50 uM CoQlO in THF/chol/LDL foUowed by a 2 h treatment with 100 uM CoQlO.
  • the ceUs were washed, fresh medium containing 50 uM CoQlO added and the ceUs incubated for an additional 48 h.
  • Table 2 The results are presented in Table 2.
  • Control O hour 149 10.0 12 hour 44 44.0 24 hour 13 78.0 48 hour 35 76.5 ⁇ .
  • This example serves to set forth the general methodology utilized to prepare and administer representative ubiquinone deUvery compositions of the present invention. The use and effectiveness of these ubiquinone deUvery compositions are described in Examples 4 to 8, which foUow.
  • CoQlO delivery compositions representative of the ubiquinone delivery compositions of this invention, are prepared and administered.
  • Other ubiquinones and ubiquinone prodrugs of this invention may be similarly formulated and administered.
  • Lipofection was utiUzed to deUver CoQlO in an in vitro model systems designed to measure the effects of the drug on stress induced ceUular apoptosis. In these studies, CoQlO and polyoxyethanyl-cholesterol sebacate ("cholesterol", Cat.
  • Lipofection of various ceU lines was accompUshed by culturing ceUs with LipofectamineTM (a 3:1 mixture of the polycationic Upid, 2,3-dioleyloxy-N-[-2- (spermmecarboan ⁇ do)ethyl]-N,N-dimethyl-l-propanaminium trifiuoroacetate, "DOSPA,” and the neutral Upid, dioleoyl phosphatidylethanolamine, "DOPA,” in water, Gibco BRL, Gaithersberg, MD) mixed with cholesterol or cholesterol/CoQlO prepared as described above.
  • LipofectamineTM a 3:1 mixture of the polycationic Upid, 2,3-dioleyloxy-N-[-2- (spermmecarboan ⁇ do)ethyl]-N,N-dimethyl-l-propanaminium trifiuoroacetate, "DOSPA,” and the neutral Upid, dioleoyl phosphatidyl
  • Induction of apoptosis was accompUshed by treating the ceUs for various periods of time with hydrogen peroxide H 2 O 2 (50 or 100 uM). Inactivation of the H 2 O 2 and cessation of the oxidative insult was accompUshed by adding 50 uM catalase to the cultures. This was an appropriate model for induction of oxidative stress as macrophage generate H 2 O 2 during activation that can occur in a variety of conditions such as, for example, inflammation.
  • CeU viabUity was determined using a standard MTT [3-(4,5-dimethythiazol-2-yl) 2,5- diphenyltetrazoUum bromide] assay (Hansen et al., J. Immun. Methods 119:203-210, 1989). This assay was based on the conversion of the tetrazoUum salt to the colored product, formazan. The reaction was monitored spectrophotometrically at 570 nm. Formation of formazan was believed to occur via functional mitochondria and therefore can be an indicator of cell growth or ceU death. Values were obtained by assessing absorption of 3 samples and taking the mean value.
  • the TCA supernatant was neutralized with 200-300 uL of an ice cold mixture of tri-n-octylamine (Sigma Chemical Co., T-863iyi,l,2-tricl ⁇ oroti ⁇ fluorcrethane (Sigma Chemical Co., T- 9159) 1:3 v/v (see James et al., Cell Prolif. 22:395-406, 1994).
  • the sample was vortexed for 30 seconds and centrifuged for 1 minute to achieve phase separation. AUquots, 10-20 uL, of the upper phase were injected onto a SynChropac RT-P (octadecyl) reverse phase column (4.6 mm X 25 cm, Synchrom, Inc., Lafayette, IN).
  • CeU lines used in these studies include CEM (ATCC accession number CCL119), a T lymphoblastoid line, established from a patient with acute lymphoblastoid leukemia; IMR-32 (ATCC accession number CCL127), a human neuroblastoma ceU line, estabUshed from an abdominal tumor mass of a Caucasian male; and Neo and bcl-2 transfected cells were obtained from John Reed (Scripps Research Foundation, La JoUa, CA). CEM ceUs were transfected with the amphotrophic retroviruses Zip-Neo and Zip-bcl-2 as described in Miyashita and Reed ( Cancer Research 52:5407-5411, 1992). EXAMPLE 4
  • This example serves to compare the abiUty of CoQlO to ameUorate ceU death with that of the gene bcl-2.
  • CoQlO is administered using a representative ubiquinone composition of the present invention.
  • Other ubiquinones and ubiquinone prodrugs of this invention may be similarly administered.
  • the gene bcl-2 is a weU-characterized gene that participates in the ceU death pathway.
  • the bcl-2 gene encodes a 25 kD protein that associates with membranes by a C-terminal anchor domain has the novel property, among proto-oncogenes, of inhibiting apoptosis and some forms of necrosis (Hockenbery et al., Nature 3£4:334-336, 1990).
  • CeUs transfected with the bcl-2 gene are protected from oxidative stress and provide a standard against which the protective effects of ubiquinones can be assessed.
  • CEM cells were transfected with bcl-2 gene under the control of a strong promoter (CEM-bcl-2 ceUs) or were transfected with a vector containing the neomycin resistant gene alone (CEM-neo ceUs).
  • CEM-bcl-2 ceUs a strong promoter
  • CEM-neo ceUs a vector containing the neomycin resistant gene alone
  • the CEM ceUs were then Upofected, as described above in Example 3, for 18 h with either LipofectamineTM and water soluble cholesterol (25 uM) or LipofectamineTM, and a ubiquinone deUvery composition comprising water soluble cholesterol and CoQlO (50 uM) prepared as described in Example 3.
  • the ceUs were aUquoted into 6-weU tissue culture plates at 2X10 3 ceUs/mL per weU in RPMI medium.
  • ceUs were washed, replated, and treated with different concentrations of
  • the data suggests additive protection where the bcl-2 gene product is present and the ceUs are treated with CoQlO.
  • combination therapy which combines apoptotic inhibitors, for example, the bcl-2 gene product and a ubiquinone, is effective and provides enhanced protection to ceUs.
  • This example serves to demonstrate the protective effects of CoQlO against H 2 O 2 - induced cell death in IMR-32 ceUs (ATCC accession number CCL127).
  • CoQlO is administered using a representative ubiquinone composition of the present invention.
  • Other ubiquinones and ubiquinone prodrugs of this invention may be similarly administered.
  • IMR-32 ceUs were Upofected, as described above in Example 3, with either LipofectamineTM and water soluble cholesterol (50 uM) or LipofectamineTM, and a ubiquinone deUvery composition comprising water soluble cholesterol and CoQlO (50 uM) prepared as described in Example 3, for either 18 h (Table 4) or 10 h (Table 5).
  • the cells were trypsin released, washed in fresh medium and replated in 6-weU tissue culture plates at 0.2 X 10 6 ceUs/weU and in 3 ml of RPMI.
  • This example serves to illustrate the protective effects of CoQ 10 provides from apoptosis induced by topoisomerase inhibitor VM-26 in human T ceUs.
  • CoQ 10 provides from apoptosis induced by topoisomerase inhibitor VM-26 in human T ceUs.
  • CoQ 10 is administered using a representative ubiquinone composition of the present invention.
  • Other ubiquinones and ubiquinone prodrugs of this invention may be similarly administered.
  • VM-26 is an epipodophyUotoxin beUeved to inhibit topoisomerase ⁇ , thereby preventing ceUs from completing S phase or undergoing chromosome segregation at mitosis.
  • VM-26 has been found to induce apoptosis in thymocytes (Walker et al. 1991).
  • This experiment used 8E5 cells, a T lymphoblastic ceU Une and a derivative of CEM that contain a single defective proviral genome of HTLV UI (HTV, LAV), with A3.01 ceUs, a T lymphoblastic ceU Une not infected with HTLV IE, as a control.
  • the T lymphoblastic cells were Upofected, as described above in Example 3, with either LipofectamineTM and water soluble cholesterol (50 uM) or LipofectamineTM, and a ubiquinone deUvery composition comprising water soluble cholesterol and CoQ 10 (50 uM) prepared as described in Example 3 for 18 hours.
  • the foUowing day the cells were treated with VM-26.
  • a stock solution of 15 nM VM-26 (Bristol Laboratories, Candiac, Quebec) was prepared in ethanol and stored at -20°C. The stock solution was diluted in RPMI to give appropriate concentrations.
  • the cells were cultured in the presence of VM-26 for 20 hours, and cell viabiUty was tested using the MTT assay as described in Example 3.
  • the data presented in Table 6 indicate that viabiUty is enhanced in CoQio treated A3.01 ceUs compared to control cultures when treated with VM-26. However, the viabiUty was not significantly affected in the 8E5 ceUs, ceUs infected by HTV-l.
  • the CoQ 10 content of the two ceU lines was similar as shown in Table 6 indicating that differences in viabiUty were not due to inability to deUver CoQio to the ceUs.
  • This example serves to evaluate the level of ATP in various cells foUowing Upofection with a representative ubiquinone delivery composition of the present invention.
  • CoQ 10 is an essential component of oxidation phosphorylation.
  • the levels of ceUular ATP are evaluated for various ceUs after CoQ 10 administration using a ubiquinone delivery composition of this invention.
  • Other ubiquinones and ubiquinone prodrugs of this invention may be similarly administered.
  • neuronal IMR-32 ceUs were Upofected, as described above in Example 3, with either LipofectamineTM and water soluble cholesterol (50 uM) or LipofectamineTM, and a ubiquinone deUvery composition comprising water soluble cholesterol and CoQ 10 (50 uM) prepared as described in Example 3.
  • ceUular ATP content was evaluated as ng/ug of ceUular protein.
  • Table 6 indicate there was a significant increase in ATP levels in ceUs treated with the CoQ 10 compared to the vehicle control (Choi). However, the increased levels deteriorate quickly and are absent by 72 hours.
  • CoQ 10 is administered using a representative ubiquinone composition of the present invention.
  • Other ubiquinones and ubiquinone prodrugs of this invention may be simUarly administered.
  • Brain ischemia was induced in six 340-420 g male Sprague-Dawley rat by two vessels occlusion as described by Preston et al. (Neuroscience Letters 149:75-78, 1993). Animals were pretreated with 0.3 mg/kg of atropine sulfate and anesthetized with 60 mg/kg of sodium pentobarbital. The rats were intubated and mechanically ventilated during surgery to maintain normal levels of blood gases. Brain ischemia was induced by reducing arterial blood pressure to 42-47 mm Hg (blood withdrawal from a tail artery) foUowed by bilateral occlusion of common carotid arteries using arterial clamps.
  • the blood was reinfused, the carotid clamps were removed and wounds were closed. Colonic and tympanic temperatures were monitored and regulated during surgery within 37.5-38.0°C using a water pad beneath the animal until self thermoregulation was reestabUshed.
  • a representative ubiquinone deUvery composition of the present invention comprising CoQ 10 and water soluble cholesterol prepared as described in Example 3 was administered to one set of rats.
  • the ubiquinone deUvery composition (effectively deUvering 3 mg CoQIO/kg rat body weight) was administered twice (by intraperitoneal injection, 0.5 mL PBS containing 1 mg CoQ 10 and 4 mg water soluble cholesterol per injection), once immediately after the surgery, and then 3 h later.
  • One set of control rats where treated with 500 uM water soluble cholesterol (cholesterol control) in the same time frame, and another set of control rats were not treated (control).
  • FoUowing death the rats were perfused with 4% buffered formalin, and brain tissue was removed and embedded in paraffin. Paraffin sections, 5 ⁇ m, of the brain were prepared, H E (hematoxyUn/eosin) stained and photographed.
  • Ischemic brain injury in this model usually leads to selective neuronal loss in stratum and particularly in hippocampus.
  • the result is readily visualized after brain section staining with H E. Initially (within 24 to 48 h after the ischemic episode), the affected neurons are darker, visibly shrunken and detached from neighboring ceUs. At later times (3 to 6 days) the ceUs are gone (probably being engulfed by phagocytic cells) leaving gaps or holes in brain tissue. These gaps or holes are eventuaUy filled by g ⁇ a ceUs leading to a severe memory loss in these ischemic animals.
  • PLASMA ng/mL
  • BRAIN ⁇ g/g
  • FIGURE 5 suminarizes the percentage of apoptotic ceUs for rats treated with the ubiquinone deUvery composition (CoQ 10 treated) and those treated with water soluble cholesterol (untreated) as a function of days after reperfusion for both the 8- and 12-minute occlusions.
  • the percent of dead hippocampal neurons (standard error of mean) at the indicated periods foUowing reperfusion was assessed by microscopy of fixed tissue sections and "ND" refers to "not determined”.
  • This example serves to demonstrate a method of reducing ubiquinone(50) to ubiquinol(50).
  • the method is generally applicable to the reduction of the quinone group of any ubiquinone or ubiquinone derivative to its corresponding ubiquinol.
  • Ubiquinol was synthesized from ubiquinone according to Cheng and Casida (J. Labi. Compd. Radiopharm. 6:66-75, 1970). Briefly, a rnixture of 1 g of coenzyme Q10, 5 mL of acetic acid and 0.3 g of zinc dust was heated at 50°C for 5 min., quenched with 5 mL of water and extracted in hexane (45 mL), in an argon atmosphere.
  • This example serves to demonstrate the synthesis of a representative ubiquinone prodrug of the present invention, CoQIO-ether-PEG.
  • the ubiquinone is CoQ 10
  • the solubilizing moiety is polyethylene glycol 5000
  • an electronically neutral solubiUzing moiety
  • the Unking group is an ether.
  • the foUowing procedure provides a general methodology for preparing a ubiquinone prodrug having a solubiUzing moiety coupled directly to a ubiquinol with an ether Unking group. Accordingly, the synthetic procedure is appUcable to the ubiquinones and solubiUzing moieties of this invention.
  • soUds were vacuum filtered and solvent was evaporated on a rotoevaporator.
  • the thick oily material obtained was dissolved in 100 mL of chloroform and washed with water (2 x 10 mL).
  • the organics were dried over anhydrous magnesium sulfate, filtered, concentrated on a rotoevaporator, and dried under vacuum at room temperature for 2 h to yield 1.5 g of a yellow soUd.
  • the crude product was loaded on a 2.5 x 28 cm flash siUca column and eluted with chloroform as the solvent. CoQio and other related impurities were eluted with chloroform and the pegylated products were eluted with 10 % methanol in chloroform to yield 1.21 g of a faint yeUow soUd.
  • the quantitation of the coenzyme Qjo-containing product is accompUshed by HPLC using UV detection at 254 nm.
  • a an aqueous solution of a coenzyme Q10 derivative is prepared and analyzed by HPLC as described above.
  • a series of coenzyme Q10 aqueous solutions of known concentration are prepared and analyzed by HPLC.
  • the results of these HPLC analyses are then used to construct a standard curve where the concentration of the coenzyme Q10 standard is plotted against the HPLC signal for the standard. Once such a standard curve has been constructed, aqueous solutions of coenzyme Q10 derivatives may be similarly analyzed and the concentration of the derivative in the solution determined.
  • This example serves to demonstrate the synthesis of a representative ubiquinone prodrug of the present invention, CoQlO-carbamate-PEG.
  • the ubiquinone is CoQ 10
  • the solubilizing moiety is polyethylene glycol 5000
  • an electronicaUy neutral solubiUzing moiety is polyethylene glycol 5000
  • the Unking group is a carbamate.
  • the foUowing procedure provides a general methodology for preparing a ubiquinone prodrug having a solubiUzing moiety coupled directly to a ubiquinol with a carbamate linking group. Accordingly, the synthetic procedure is applicable to the ubiquinones and solubilizing moieties of this invention.
  • the foUowing synthesis of CoQlO-carbamate-PEG is a two-step process.
  • the succinimidyl carbamate of amino-methoxy-PEG 5000 was prepared by dissolving 1.0 g (0.20 mmol) amino-methoxy-PEG 5000 (Shearwater Polymer, Inc., HuntsvUle, AL) in 15 mL dry dioxane and warming to 50 C to achieve solution. To the cooled solution was added a solution of 359 mg (1.4 mmol) N,N'-disuccinimidyl carbonate in 10 mL acetone.
  • the crude product was loaded on a 2.5 x 28 cm flash silica column and eluted with chloroform as the solvent. CoQio and other related impurities were eluted with chloroform and the pegylated products were eluted with 50 % methanol in chloroform to yield 0.49 g of a faint yeUow soUd.
  • CoQlO-carbamate-PEG was obtained in 40% yield.
  • This example serves to demonstrate the synthesis of a representative ubiquinone prodrug of the present invention, CoQ2-ether-sulfonate.
  • the ubiquinone is CoQ2
  • the solubilizing moiety is a sulfonate group
  • an electronically charged solubilizing moiety
  • the Unking group is an ether.
  • the foUowing procedure provides a general methodology for preparing a ubiquinone prodrug having a solubiUzing moiety coupled directly to a ubiquinol with an ether Unking group. Accordingly, the synthetic procedure is appUcable to the ubiquinones and solubiUzing moieties of this invention.
  • This example serves to demonstrate a representative ubiquinone prodrug of the present invention in which the ubiquinone is CoQ 10, the solubiUzing moiety is a polyethylene glycol and the Unking group is a carbonate.
  • the foUowing procedure provides a general methodology for preparing a ubiquinone prodrug having a solubilizing moiety coupled directly to a ubiquinol with a carbonate linking group. Accordingly, the synthetic procedure is appUcable to the ubiquinones and solubilizing moieties of this invention.
  • succinimidyl carbonate of PEG Treatment of the succinimidyl carbonate of PEG with reduced coenzyme Qio in the presence of appropriate base (such as sodium hydride) in appropriate solvent (such as tetrahydrofuran).
  • Succinimidyl carbonate of methoxy-PEG-5000 is commerciaUy avaUable (Shearwater Polymers, Inc., HuntsvUle, AL), and may be synthesized from methoxy-PEG (see, e.g., Miron and WUchek, Bioconiugate Chem. 4:568-569, 1993; Greenwald et al., J. Org. Chem 60_:331- 336, 1995).
  • succinimidyl carbonate of methoxy-PEG of various sizes may also be synthesized in this manner.
  • Solubihty may be ascertained as outlined above in Example 10.
  • This example serves to demonstrate a representative ubiquinone prodrug of the present invention in which the ubiquinone is CoQ 10, the solubilizing moiety is a polyethylene glycol and the linking group is an ester.
  • the foUowing procedure provides a general methodology for preparing a ubiquinone prodrug having a solubiUzing moiety coupled directly to a ubiquinol with an ester linking group. Accordingly, the synthetic procedure is appUcable to the ubiquinones and solubiUzing moieties of this invention.
  • Solubihty may be ascertained as outlined above in Example 10.
  • N-hydroxysuccinimidyl active ester of methoxy-PEG-succinamide is commerciaUy avaUable (Shearwater Polymers, Inc., HuntsvUle, AL), it is synthesized according to a
  • Example 11 see, e.g., Miron and WUchek, Bioconjugate Chem. 4:568-569, 1993; Greenwald et al.. J. Org. Chem. 60:331-336. 1995).
  • EXAMPLE 15 See, e.g., Miron and WUchek, Bioconjugate Chem. 4:568-569, 1993; Greenwald et al.. J. Org. Chem. 60:331-336. 1995).
  • This example serves to Ulustrate the bioavaUabiUty of CoQ 10 foUowing administration of representative ubiquinone prodrugs and ubiquinone compositions of the present invention.
  • the effective equivalent of 1 mg of CoQ 10 was administered to rats by intraperitoneal injection of sterile PBS solutions of (1) a representative ubiquinone delivery composition comprising CoQ 10 and water soluble cholesterol prepared as described in Example 3; and representative ubiquinone prodrugs (2) CoQlO-carbamate-PEG prepared as described in Example 11, (3) CoQIO-ether-PEG prepared as described in Example 10, and (4) CoQ10-(ether-PEG) 2 prepared as described in Example 10.
  • Plasma Liver ug/g Brain (ug/g) (ng/mL)
  • This example serves to Ulustrate a manufacturing process for the preparation of the water soluble ubiquinone prodrugs of the present invention. While it is appreciated that the ubiquinone prodrugs can be prepared by a variety of methods including those presented in the Examples above, the following manufacturing process takes advantage of the difference in the solubihty properties of the ubiquinone starting material and prodrug product to effect the separation and isolation of the prodrug process products. Generally, ubiquinones (including their corresponding ubiquinols) are highly water insoluble. In contrast, the ubiquinone prodrugs are highly water soluble.
  • the manufacturing process for preparing a ubiquinone prodrug from ubiquinone includes at least two steps.
  • a ubiquinone is reduced to its ubiquinol (see, e.g., Example 9)
  • a suitably reactive solubilizing moiety is coupled to the ubiquinol to form the prodrug product (see, e.g.. Examples 10-14).
  • the process includes the use of organic solvents for the reduction and coupling steps.
  • the coupling reaction wiU consume essentially aU of the solubilizing moiety thus leaving unconverted ubiquinol in the reaction mixture.
  • the reaction mixture contains unreacted ubiquinol (or its oxidation product ubiquinone) and the water soluble prodrug.
  • the use of a limiting amount of a suitably reactive solubilizing moiety is not essential.
  • the manufacturing process is a filtration process and involves separation by filtration of the aqueous prodrug solution from the aqueous insoluble organic residue of the reaction mixture.
  • the manufacturing process is an extraction process and involves extraction of the water soluble prodrug product from the reaction mixture.
  • Isolation of the ubiquinone prodrugs by the filtration process involves the steps of removing the organic solvents from the reaction mixture by, for example, evaporation to provide a reaction mixture residue; adding an aqueous solvent such as water to the reaction mixture residue to dissolve the product prodrug and provide a heterogeneous product solution comprising an aqueous prodrug solution and an aqueous insoluble organic residue comprising unreacted ubiquinol and ubiquinone; filtering the heterogeneous product solution to separate the aqueous prodrug solution from the aqueous insoluble organic residue; and concentrating the aqueous prodrug solution to dryness to provide the prodrug product.
  • an aqueous solvent such as water
  • Isolation of the ubiquinone prodrugs by the extraction process involves the steps of adding an aqueous solvent to provide a biphasic solution comprising an aqueous prodrug solution and a water-immiscible organic solution comprising unreacted ubiquinol and ubiquinone; separating the aqueous prodrug solution and the water-immiscible organic solution; and concentrating the aqueous prodrug solution to dryness to provide the prodrug product.
  • the extraction process may further include the step of adding a water-immiscible organic solvent such as hexane or diethyl ether.
  • This example serves to evaluate CoQ 10 utilized against stroke in primates.
  • global or forebrain ischemia is induced in anesthetized primates using the technique of surgical occlusion of the carotids (Sengupta et al., J. Neurol. Neurosurg. Psychiatry 36:736- 741, 1973) or using the technique of 4 vessel occlusion, carotid and vertebral arteries (Wolin et al., Resuscitation 1:39-44, 1992). Both of these methods produce global forebrain ischemia with damage selectively limited to vulnerable neuronal populations.
  • ischemia-sensitive neurons include the hippocampal CAl pyramidal neurons, the cerebeUar Puritinje ceUs, striatal neurons of medium or smaU size and pyramidal neurons in the midneocortical layers.
  • FoUowing the induction of the ischemic event, water soluble ubiquinone prodrugs or ubiquinone deUvery compositions are solubilized in a solution at concentrations ranging from 50 to 200 mg/ml- is administered intravenously at various time points (e.g., at time 0, 30, 60, 120, 240, and 480 minutes) in either single or multiple injections.
  • the animals receive various doses of the ubiquinone, ranging from 50 to 300 mg.
  • the vehicle control is also administered for comparative purposes.
  • FoUowing recovery from anesthesia, the animals are studied for motor and behavioral activity. In addition, memory and ability to remember new tasks are evaluated using techniques specific to the species of primate.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne des compositions à base d'ubiquinones solubles dans l'eau ainsi que des précurseurs de médicaments (I). Cette invention concerne également des procédés d'administration de ces compositions et leur utilisation pour améliorer l'apoptose.
EP95943698A 1994-12-06 1995-12-06 Compositions a base d'ubiquinones solubles dans l'eau, precurseurs de medicaments, ainsi que les procedes y ayant trait Withdrawn EP0796108A2 (fr)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US484718 1983-04-13
US35022094A 1994-12-06 1994-12-06
US350220 1994-12-06
US48421395A 1995-06-07 1995-06-07
US48060695A 1995-06-07 1995-06-07
US48697395A 1995-06-07 1995-06-07
US48471895A 1995-06-07 1995-06-07
US48545095A 1995-06-07 1995-06-07
US48840095A 1995-06-07 1995-06-07
US484213 1995-06-07
US486973 1995-06-07
US488400 1995-06-07
US485450 1995-06-07
US480606 1995-06-07
PCT/US1995/015888 WO1996017626A2 (fr) 1994-12-06 1995-12-06 Compositions a base d'ubiquinones solubles dans l'eau, precurseurs de medicaments, ainsi que les procedes y ayant trait

Publications (1)

Publication Number Publication Date
EP0796108A2 true EP0796108A2 (fr) 1997-09-24

Family

ID=27569706

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95943698A Withdrawn EP0796108A2 (fr) 1994-12-06 1995-12-06 Compositions a base d'ubiquinones solubles dans l'eau, precurseurs de medicaments, ainsi que les procedes y ayant trait

Country Status (5)

Country Link
EP (1) EP0796108A2 (fr)
JP (1) JPH10509732A (fr)
AU (1) AU4510596A (fr)
CA (1) CA2207093A1 (fr)
WO (1) WO1996017626A2 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3889481B2 (ja) * 1996-08-16 2007-03-07 株式会社カネカ 医薬組成物
IT1290907B1 (it) * 1997-01-31 1998-12-14 Idi Farmaceutici Spa Composizione per prodotto dietetico efficace nel combattere lo stress ossidativo e il decadimento cellulare.
US6544797B1 (en) * 1997-04-09 2003-04-08 Biosite Diagnostics, Inc. Compositions and methods for inhibiting light-induced inactivation of biological reagents
DE19905880A1 (de) * 1999-02-11 2000-08-17 Mse Pharmazeutika Gmbh Spray enthaltend Ubichinon Qn
US20080070981A1 (en) 2000-02-23 2008-03-20 Henryk Borowy-Borowski Water-soluble compositions of bioactive lipophilic compounds
US6045826A (en) * 1999-04-02 2000-04-04 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US6632443B2 (en) 2000-02-23 2003-10-14 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
AU1474901A (en) * 1999-11-09 2001-06-06 Hybridon, Inc. Potentiation of prodrug efficacy
US6864231B2 (en) 2001-01-09 2005-03-08 Pharmachem Laboratories, Inc. Glycoprotein matrix compositions and methods related thereto
US6806069B2 (en) 2001-01-09 2004-10-19 Pharmachem Laboratories, Inc. Ubiquinone composition and methods related thereto
TWI237018B (en) 2001-07-13 2005-08-01 Kaneka Corp Method of producing reduced coenzyme Q10 crystals
TW200604159A (en) * 2001-07-13 2006-02-01 Kaneka Corp Method of producing reduced coenzyme Q10 as oily product
CN100503543C (zh) * 2001-07-13 2009-06-24 钟渊化学工业株式会社 制备还原型辅酶q10油性产物的方法
TWI310029B (fr) * 2001-07-13 2009-05-21 Kaneka Corp
TWI235146B (en) * 2001-07-16 2005-07-01 Kaneka Corp Method of stabilizing reduced coenzyme q10 and method of acidic crystallization
ITRM20010755A1 (it) 2001-12-20 2003-06-20 Simonelli Giuseppe Uso del chinone q10 per il trattamento delle malattie oculari.
TWI349039B (en) * 2001-12-27 2011-09-21 Kaneka Corp Processes for producing coenzyme q10
CN100344595C (zh) * 2003-01-10 2007-10-24 株式会社钟化 纯化还原型辅酶q10的方法
EA011351B1 (ru) * 2003-05-23 2009-02-27 Нектар Терапеутикс Ал, Корпорейшн Полимерные реагенты, способы их получения, а также содержащие их конъюгаты и фармацевтические препараты
US7947261B2 (en) 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
AU2004298996A1 (en) 2003-12-10 2005-06-30 Nektar Therapeutics Al, Corporation Compositions comprising two different populations of polymer-active agent conjugates
US7790190B2 (en) 2004-03-20 2010-09-07 Yasoo Health, Inc. Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid
US20070203080A1 (en) * 2006-02-15 2007-08-30 The Regents Of The University Of California New Drug Delivery System for Crossing the Blood Brain Barrier
JP5180556B2 (ja) 2006-10-13 2013-04-10 昭和電工株式会社 ユビキノン誘導体またはその塩を含む皮膚外用剤および化粧料ならびにこれらの使用方法
WO2008116021A1 (fr) * 2007-03-19 2008-09-25 Zymes, Llc Composés organoleptiques présentant des propriétés améliorées
ES2755840T3 (es) 2007-03-22 2020-04-23 Berg Llc Formulaciones tópicas que tienen biodisponibilidad aumentada
WO2008134766A1 (fr) * 2007-04-30 2008-11-06 Zymes, Llc Applications d'ubiquinones et d'ubiquinols
KR20100136997A (ko) 2008-04-11 2010-12-29 싸이토테크 랩스, 엘엘씨 암세포에서 아폽토시스를 유도하는 방법 및 용도
CA2761717A1 (fr) 2009-05-11 2010-11-18 Berg Biosystems, Llc Methodes de traitement de maladies oncologiques a l'aide de decaleurs epimetaboliques, de molecules intracellulaires multidimensionnelles ou d'influenceurs environnementaux
EP2498602A4 (fr) 2009-11-10 2014-05-21 Mycell Technologies Llc Formulations stabilisées d'acides gras
CN102892412B (zh) 2010-03-12 2015-09-30 博格制药有限责任公司 辅酶Q10(CoQ10)的静脉内制剂及其使用方法
AU2012240222B2 (en) 2011-04-04 2017-04-27 Berg Llc Methods of treating central nervous system tumors
US10973763B2 (en) 2011-06-17 2021-04-13 Berg Llc Inhalable pharmaceutical compositions
WO2014087972A1 (fr) * 2012-12-03 2014-06-12 株式会社カネカ Dérivé de la coenzyme q10 sous sa forme réduite et procédé de production associé
MX2015014097A (es) 2013-04-08 2016-06-07 Berg Llc Tratamiento de cancer empleando terapias combinadas de coenzima q10.
IL276423B2 (en) 2013-09-04 2024-05-01 Berg Llc Pharmaceutical preparations containing coenzyme Q10 for use in cancer treatment
RS62657B1 (sr) 2017-10-24 2021-12-31 Difass Int S P A Kompozicija koja sadrži koenzim q10 i piperin
CA3112583A1 (fr) 2018-07-09 2020-01-16 New Age Nanotech Llc Formulations stabilisees de compositions cannabinoides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6020368B2 (ja) * 1974-10-11 1985-05-21 エーザイ株式会社 １，４ベンゾハイドロキノン誘導体の製法
CA1091680A (fr) * 1976-10-19 1980-12-16 Shinji Terao Procede d'obtention de quinones
JPS54160327A (en) * 1978-06-06 1979-12-19 Kuraray Co Ltd Preparation of coenzyme q
JPS5564538A (en) * 1978-11-06 1980-05-15 Ajinomoto Co Inc Preparation of dihydrocoenzyme q compound
JPS60255749A (ja) * 1984-05-31 1985-12-17 Univ Nagoya キノン誘導体
IL78611A0 (en) * 1986-04-23 1986-08-31 Yeda Res & Dev Production of polyprenoid and ubiquinone-type compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9617626A2 *

Also Published As

Publication number Publication date
WO1996017626A3 (fr) 1996-08-29
AU4510596A (en) 1996-06-26
CA2207093A1 (fr) 1996-06-13
JPH10509732A (ja) 1998-09-22
WO1996017626A2 (fr) 1996-06-13

Similar Documents

Publication Publication Date Title
WO1996017626A2 (fr) Compositions a base d'ubiquinones solubles dans l'eau, precurseurs de medicaments, ainsi que les procedes y ayant trait
Sharma et al. Targeting mitochondrial dysfunction and oxidative stress in activated microglia using dendrimer-based therapeutics
Atallah et al. Challenges for cysteamine stabilization, quantification, and biological effects improvement
Sou et al. Loading of curcumin into macrophages using lipid-based nanoparticles
Nagi et al. Thymoquinone protects against carbon tetrachloride hetatotoxicity in mice via an antioxidant mechanism
US4764508A (en) Complexes of flavanolignans with phospholipids, preparation thereof and associated pharmaceutical compositions
US9907787B2 (en) Method of supplementing the diet and ameliorating oxidative stress
US8426368B2 (en) Method of ameliorating oxidative stress and supplementing the diet
WO2006005759A2 (fr) Utilisation d'un antioxydant cible de maniere mitochondriale pour traiter les maladies hepatiques et les cancers epitheliaux.
JP2002512188A (ja) 抗酸化剤及び神経保護剤としてのカンナビノイド類
KR20080059228A (ko) 미토콘드리아로의 생물학적 활성물질의 표적 전달에 의해유기체에 작용하는 방법, 상기 방법을 수행하기 위한 약제조성물, 및 목적을 위해 이용되는 화합물
Fattahi et al. Enhancement of the brain delivery of methotrexate with administration of mid-chain ester prodrugs: In vitro and in vivo studies
WO1994022484A1 (fr) Distribution selective de radioprotecteurs utilisant une molecule porteuse specifique d'un recepteur
Vangapandu et al. 8-Quinolinamines conjugated with amino acids are exhibiting potent blood-schizontocidal antimalarial activities
Song et al. Long-circulation and brain targeted Isoliquiritigenin micelle Nanoparticles: formation, characterization, tissue distribution, pharmacokinetics and effects for ischemic stroke
Cheng et al. A novel ibuprofen derivative with anti-lung cancer properties: Synthesis, formulation, pharmacokinetic and efficacy studies
V Diogo et al. Re-wiring the circuit: mitochondria as a pharmacological target in liver disease
Singh et al. Hepatoprotective agent tethered isoniazid for the treatment of drug-induced hepatotoxicity: Synthesis, biochemical and histopathological evaluation
Babizhayev Analysis of Lipid Peroxidation and Electron Microscopic Survey of Maturation Stages during Human Cataractogenesis: Pharmacokinetic Assay of Can-C™ N-Acetylcarnosine Prodrug Lubricant Eye Drops for Cataract Prevention
Hao et al. Preparation, characterization, antioxidant evaluation of new curcumin derivatives and effects of forming HSA-bound nanoparticles on the stability and activity
SG172072A1 (en) Use of racemates of pinocembrin in preparing medicaments for treating stroke
KR20000016238A (ko) 신경 독성 손상을 치료하기 위한 부크민스테르풀레렌의 용도
Bai et al. Carrier-free doxorubicin/rhein supramolecular co-assembly for cancer therapy
CN110025573B (zh) 降低有机氟化物肝毒性的儿茶素微粒的制备方法
Togashi et al. Suppressive effects of uracil, tyrosine, and phenylalanine contained in human-placenta extract on acute ethanol-induced liver injury in mice

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970701

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20000614

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20001228